en
Scientific article
English

CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2

Published inJournal of acquired immune deficiency syndromes, vol. 54, no. 4, p. 394-397
Publication date2010
Abstract

OBJECTIVES: To determine factors associated with CD4 responses to maraviroc (MVC)-containing regimens in treatment-experienced patients. METHODS: Forty-eight-week data from MOTIVATE 1 and 2 was used to assess MVC once or twice daily versus placebo (PBO), each with optimized background therapy (N = 1047). A repeated measures model evaluated longitudinal CD4 changes, multivariate linear regression evaluated predictors of week 48 increases, and Cox proportional hazard modeling evaluated time to category C events. RESULTS: Median CD4 increases were greater on MVC once or twice daily than PBO (92, 103, and 24 cells/mm3, respectively; P < 0.05), and the difference remained significant among patients achieving less than 50 HIV-1 RNA copies/mL (126, 125, and 96 cells/mm3; P < 0.05) or when adjusted for other predictors of CD4 increase including change in HIV-1 RNA. Time to a category C event was longer on MVC; in multivariate models, higher on-treatment CD4 count, but not MVC treatment, was protective against new events (hazard ratio 0.8 per +25 cells/mm3; 95% confidence interval 0.78-0.87). CONCLUSIONS: MOTIVATE patients receiving MVC had larger CD4+ T-cell increases than those receiving PBO, even after adjusting for the greater virologic potency of MVC-containing regimens. This additional CD4 response was associated with a longer time to the development of AIDS-defining events on MVC.

Keywords
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes/drug effects/immunology
  • Clinical Trials as Topic
  • Cyclohexanes/adverse effects/*therapeutic use
  • Drug Resistance, Viral
  • HIV Fusion Inhibitors/adverse effects/*therapeutic use
  • Humans
  • Opportunistic Infections/epidemiology
  • T-Lymphocytes/drug effects/virology
  • Time Factors
  • Treatment Outcome
  • Triazoles/adverse effects/*therapeutic use
Research group
Citation (ISO format)
ASMUTH, David M. et al. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. In: Journal of acquired immune deficiency syndromes, 2010, vol. 54, n° 4, p. 394–397. doi: 10.1097/QAI.0b013e3181c5c83b
Main files (1)
Article
accessLevelRestricted
Identifiers
ISSN of the journal1525-4135
529views
0downloads

Technical informations

Creation05/23/2012 8:44:04 AM
First validation05/23/2012 8:44:04 AM
Update time03/14/2023 5:31:32 PM
Status update03/14/2023 5:31:32 PM
Last indexation02/12/2024 8:08:14 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack